Jiangsu Ruike Biotech announced that the new drug marketing application for the company's new adjuvant recombinant herpes zoster vaccine REC610 was officially accepted by the Drug Evaluation Center of the State Drug Administration on December 29, 2025. The nine-valent HPV vaccine was originally scheduled to be submitted for marketing before June 30, 2026. As of the announcement date, the application submission process had not been completed. The company has adjusted the core management team of the HPV production sector to strengthen the overall management of the entire process to ensure the efficient progress of all aspects. Currently, the overall HPV R&D pipeline progress is manageable, and the company will promptly fulfill its information disclosure obligations in accordance with relevant regulations.

Jiangsu Ruike Biotech announced that the new drug marketing application for the company's new adjuvant recombinant herpes zoster vaccine REC610 was officially accepted by the Drug Evaluation Center of the State Drug Administration on December 29, 2025. The nine-valent HPV vaccine was originally scheduled to be submitted for marketing before June 30, 2026. As of the announcement date, the application submission process had not been completed. The company has adjusted the core management team of the HPV production sector to strengthen the overall management of the entire process to ensure the efficient progress of all aspects. Currently, the overall HPV R&D pipeline progress is manageable, and the company will promptly fulfill its information disclosure obligations in accordance with relevant regulations.